WSGR logoWSGR logo
WSGR logo
  • Experience
  • People
  • Insights
  • About Us
  • Careers

  • Practice Areas
  • Industries

  • Corporate
  • Intellectual Property
  • Litigation
  • Patents and Innovations
  • Regulatory
  • Technology Transactions

  • Capital Markets
  • Corporate Governance
  • Corporate Life Sciences
  • Derivatives
  • Emerging Companies and Venture Capital
  • Employee Benefits and Compensation
  • Energy and Climate Solutions
  • Executive Advisory Program
  • Finance and Structured Finance
  • Fund Formation
  • Greater China
  • Mergers & Acquisitions
  • Private Equity
  • Public Company Representation
  • Real Estate
  • Restructuring
  • Shareholder Engagement and Activism
  • Tax
  • U.S. Expansion
  • Wealthtech

  • Special Purpose Acquisition Companies (SPACs)

  • Environmental, Social, and Governance

  • AI and Data Center Infrastructure
  • Energy Regulation and Competition
  • Project Development and M&A
  • Project Finance and Tax Credit Transactions
  • Sustainability and Decarbonization
  • Transportation Electrification

  • U.S. Expansion Library and Resources

  • Post-Grant Review
  • Trademark and Advertising

  • Antitrust Litigation
  • Arbitration
  • Board and Internal Investigations
  • Class Action Litigation
  • Commercial Litigation
  • Consumer Litigation
  • Corporate Governance Litigation
  • Employment Litigation
  • Executive Branch Updates
  • Government Investigations
  • Internet Strategy and Litigation
  • Patent Litigation
  • Securities Litigation
  • State Attorneys General
  • Supreme Court and Appellate Practice
  • Trade Secret Litigation
  • Trademark and Copyright Litigation
  • Trial
  • White Collar Crime

  • Advertising, Promotions, and Marketing
  • Antitrust and Competition
  • Committee on Foreign Investment in the U.S. (CFIUS)
  • Communications
  • Data, Privacy, and Cybersecurity
  • Export Control and Sanctions
  • FCPA and Anti-Corruption
  • FDA Regulatory, Healthcare, and Consumer Products
  • Federal Trade Commission
  • Fintech and Financial Services
  • Government Contracts
  • National Security and Trade
  • Payments
  • State Attorneys General
  • Strategic Risk and Crisis Management
  • Tariffs, Customs, and Import Compliance

  • Antitrust and Intellectual Property
  • Antitrust Civil Enforcement
  • Antitrust Compliance and Business Strategy
  • Antitrust Criminal Enforcement
  • Antitrust Litigation
  • Antitrust Merger Clearance
  • European Competition Law
  • Third-Party Merger and Non-Merger Antitrust Representation

  • Anti-Money Laundering
  • Foreign Ownership, Control, or Influence (FOCI)
  • Team Telecom

  • AI in Healthcare
  • Animal Health
  • Artificial Intelligence and Machine Learning
  • Aviation
  • Biotech
  • Blockchain and Cryptocurrency
  • Clean Energy
  • Climate and Clean Technologies
  • Communications and Networking
  • Consumer Products and Services
  • Data Storage and Cloud
  • Defense Tech
  • Diagnostics, Life Science Tools, and Deep Tech
  • Digital Health
  • Digital Media and Entertainment
  • Electronic Gaming
  • Fintech and Financial Services
  • FoodTech and AgTech
  • Global Generics
  • Internet
  • Life Sciences
  • Medical Devices
  • Mobile Devices
  • Mobility
  • NewSpace
  • Quantum Computing
  • Semiconductors
  • Software

  • Offices
  • Country Desks
  • Events
  • Community
  • Our Diversity
  • Sustainability
  • Our Values
  • Board of Directors
  • Management Team

  • Austin
  • Boston
  • Boulder
  • Brussels
  • Century City
  • Hong Kong
  • London
  • Los Angeles
  • New York
  • Palo Alto
  • Salt Lake City
  • San Diego
  • San Francisco
  • Seattle
  • Shanghai
  • Washington, D.C.
  • Wilmington, DE

  • Law Students
  • Judicial Clerks
  • Experienced Attorneys
  • Patent Agents
  • Business Professionals
  • Alternative Legal Careers
  • Contact Recruiting
Weigang Lu
Law Clerk
Patents and Innovations
Boston
wlu@wsgr.com

D617-598-7868

Download vCard
Open PDF

Dr. Weigang Lu is a law clerk in the Boston office of Wilson Sonsini Goodrich & Rosati, where he is a member of the patents and innovations practice. His technical expertise spans across a variety of fields, including biotechnology, pharmaceutics, and chemistry.

Prior to joining Wilson Sonsini, Weigang was a patent agent in another law firm, where he gained extensive experience in patent prosecution and IP due diligence in areas including antibodies, diagnostics, RNA therapeutics, gene/cell therapies, small molecule drugs, polymers, and batteries. Before his legal career, Weigang was a postdoctoral fellow in the Department of Immunology at Harvard Medical School, where he investigated use of gut microbiome-related molecules to improve immuno-oncology. During his doctoral training at the Complex Carbohydrate Research Center at the University of Georgia, Weigang studied human glycan synthesis and glycobiology.

Weigang is admitted to the U.S. Patent and Trademark Office. He is not yet admitted to any jurisdiction and therefore not yet authorized to practice law.

Experience

Dr. Weigang Lu is a law clerk in the Boston office of Wilson Sonsini Goodrich & Rosati, where he is a member of the patents and innovations practice. His technical expertise spans across a variety of fields, including biotechnology, pharmaceutics, and chemistry.

Prior to joining Wilson Sonsini, Weigang was a patent agent in another law firm, where he gained extensive experience in patent prosecution and IP due diligence in areas including antibodies, diagnostics, RNA therapeutics, gene/cell therapies, small molecule drugs, polymers, and batteries. Before his legal career, Weigang was a postdoctoral fellow in the Department of Immunology at Harvard Medical School, where he investigated use of gut microbiome-related molecules to improve immuno-oncology. During his doctoral training at the Complex Carbohydrate Research Center at the University of Georgia, Weigang studied human glycan synthesis and glycobiology.

Weigang is admitted to the U.S. Patent and Trademark Office. He is not yet admitted to any jurisdiction and therefore not yet authorized to practice law.

Education
  • J.D., Northeastern University School of Law, 2025
  • Ph.D., Organic Chemistry, University of Georgia, 2018
  • M.S., Pharmaceutical Sciences, Peking University, 2013
  • B.S., Pharmaceutical Science, Peking University, 2011
Admissions
  • U.S. Patent and Trademark Office
  • Not yet admitted to practice in any jurisdiction
Credentials
Education
  • J.D., Northeastern University School of Law, 2025
  • Ph.D., Organic Chemistry, University of Georgia, 2018
  • M.S., Pharmaceutical Sciences, Peking University, 2013
  • B.S., Pharmaceutical Science, Peking University, 2011
Admissions
  • U.S. Patent and Trademark Office
  • Not yet admitted to practice in any jurisdiction

Select Publications

  • Co-author, “The 3-O-sulfation of heparan sulfate modulates protein binding and lyase degradation,” 118 Proc. Natl. Acad. Sci. USA 1-12, 2021
  • Co-author, “Fully Synthetic Heparan Sulfate-Based Neural Tissue Construct That Maintains the Undifferentiated State of Neural Stem Cells,” 14 ACS Chemical Biology 1921-1929, 2019
  • Co-author, “Controlled Chemoenzymatic Synthesis of Heparan Sulfate Oligosaccharides,” 57 Angew. Chem. Intl. Ed. 5340-5344, 2018
  • Co-author, “Negative Electron Transfer of Dissociation Sequencing of 3-O-Sulfation Containing Heparan Sulfate Oligosaccharides,” 29 J. Am. Soc. Mass. Spectrom. 1262-1272, 2018
  • Co-author, “Heparan Sulfate Microarray Reveals Heparan Sulfate-Protein Binding Exhibits Different Ligand Requirements,” 139 J. Am. Chem. Soc. 9534-9543, 2017
  • Co-author, “Integrated Approach to Identify Heparan Sulfate Ligand Requirements of Robo1,” 138 J. Am. Chem. Soc. 13059-13067, 2016
  • Co-author, “General Aspects in O-Glycosidic Bond Formation,” Chapter 3, Glycochemical Synthesis: Strategies and Applications 69-95, 2016
Insights

Select Publications

  • Co-author, “The 3-O-sulfation of heparan sulfate modulates protein binding and lyase degradation,” 118 Proc. Natl. Acad. Sci. USA 1-12, 2021
  • Co-author, “Fully Synthetic Heparan Sulfate-Based Neural Tissue Construct That Maintains the Undifferentiated State of Neural Stem Cells,” 14 ACS Chemical Biology 1921-1929, 2019
  • Co-author, “Controlled Chemoenzymatic Synthesis of Heparan Sulfate Oligosaccharides,” 57 Angew. Chem. Intl. Ed. 5340-5344, 2018
  • Co-author, “Negative Electron Transfer of Dissociation Sequencing of 3-O-Sulfation Containing Heparan Sulfate Oligosaccharides,” 29 J. Am. Soc. Mass. Spectrom. 1262-1272, 2018
  • Co-author, “Heparan Sulfate Microarray Reveals Heparan Sulfate-Protein Binding Exhibits Different Ligand Requirements,” 139 J. Am. Chem. Soc. 9534-9543, 2017
  • Co-author, “Integrated Approach to Identify Heparan Sulfate Ligand Requirements of Robo1,” 138 J. Am. Chem. Soc. 13059-13067, 2016
  • Co-author, “General Aspects in O-Glycosidic Bond Formation,” Chapter 3, Glycochemical Synthesis: Strategies and Applications 69-95, 2016

Biological Sciences and Biotechnology

  • Antibody
  • Bioconjugation
  • Biologics
  • Cancer therapeutics
  • CAR-T cells
  • Cell therapy
  • Glycobiology
  • Immuno-oncology
  • Immunology
  • T cell biology

Therapeutics and Drug Discovery

  • Antimicrobial agents
  • Biosimilars
  • CRISPR
  • Drug conjugates
  • Drug conjugates based drug discovery
  • Drug delivery
  • Gene editing
  • Gene therapy
  • Immunotherapy targets
  • Neuropharmacology
  • Peptide therapeutics
  • Pharmacodynamics
  • Pharmacogenomics
  • Pharmacokinetics
  • Pharmacology
  • RNA interference (RNAi)
  • Small molecule synthesis
  • Small molecules
  • Vaccines

Chemistry and Material Science

  • Catalysis
  • Chemical synthesis
  • Chemistry
  • Chemoenzymatic synthesis
  • Materials chemistry
  • Organic chemistry
  • Peptidomimetics
  • Polymers
  • Protein engineering

Miscellaneous

  • Formulations
Technical Fluency

Biological Sciences and Biotechnology

  • Antibody
  • Bioconjugation
  • Biologics
  • Cancer therapeutics
  • CAR-T cells
  • Cell therapy
  • Glycobiology
  • Immuno-oncology
  • Immunology
  • T cell biology

Therapeutics and Drug Discovery

  • Antimicrobial agents
  • Biosimilars
  • CRISPR
  • Drug conjugates
  • Drug conjugates based drug discovery
  • Drug delivery
  • Gene editing
  • Gene therapy
  • Immunotherapy targets
  • Neuropharmacology
  • Peptide therapeutics
  • Pharmacodynamics
  • Pharmacogenomics
  • Pharmacokinetics
  • Pharmacology
  • RNA interference (RNAi)
  • Small molecule synthesis
  • Small molecules
  • Vaccines

Chemistry and Material Science

  • Catalysis
  • Chemical synthesis
  • Chemistry
  • Chemoenzymatic synthesis
  • Materials chemistry
  • Organic chemistry
  • Peptidomimetics
  • Polymers
  • Protein engineering

Miscellaneous

  • Formulations
Focus Areas
  • Intellectual Property
  • Life Sciences
  • Patents and Innovations
Recent Insights
Client Highlights
Wilson Sonsini Advises Verve Therapeutics on IP Matters Related to Merger with Lilly
On June 17, 2025,  Eli Lilly and Company and Verve Therapeutics, a Boston-based clinical-stage company developing genetic medicines for cardiovascular disease, announced a definitive agreement for Lilly to acquire Verve. Wilson Sonsini Goodrich & Rosati advised Verve Therapeutics on IP matters related to the transaction.
Learn More
Client Highlights
Wilson Sonsini Advises Insilico Medicine on $80 Million Agreement with Exelixis
On September 12, 2023, Exelixis, Inc. and Insilico Medicine announced that the companies have entered into an exclusive license agreement granting Exelixis global rights to develop and commercialize ISM3091, a potentially best-in-class small molecule inhibitor of USP1, which has emerged as a synthetic lethal target in the context of BRCA-mutated tumors. Under the terms of the agreement, Insilico granted Exelixis an exclusive, worldwide license to develop and commercialize ISM3091, and other USP1-targeting compounds, in exchange for an upfront payment to Insilico of $80 million anticipated in the third quarter 2023. Insilico is also eligible to receive future development, commercial, and sales-based milestone payments, as well as tiered royalties on net sales.
Learn More
  • people
  • insights
  • about us
  • careers
  • Binder
  • Alumni
  • Mailing List Signup
  • Client FTP Portal
  • Privacy Policy
  • Terms of Use
  • Accessibility
WSGR logo
Twitter
LinkedIn
Facebook
Instagram
Youtube
Copyright © 2026 Wilson Sonsini Goodrich & Rosati. All Rights Reserved.